Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine
By Chris Wack
Imunon shares rose after the company received clearance from the U.S. Food and Drug Administration to begin a Phase 1 clinical trial with a seasonal Covid-19 booster vaccine.
Shares were up 8% to $1.23 in recent trading. The stock hit its 52-week high of $2 on March 28.
The company filed an investigational new drug application for IMNN-101 in late February, and pending resolution of limited comments from the FDA, expects to begin patient enrollment in the second quarter of 2024.
The primary objectives of the Phase 1 study are to evaluate safety, tolerability, neutralizing antibody response, and the vaccine's durability in healthy adults.
Secondary objectives of the study include evaluating the ability of the IMNN-101 vaccine to elicit binding antibodies and cellular responses and their associated durability.
The phase 1 study will enroll 24 subjects evaluating three escalating doses of IMNN-101 at two U.S. clinical trial sites.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 18, 2024 10:38 ET (14:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?